Bio-Path Holdings Inc (NASDAQ:BPTH)’s share price traded up 15.5% during mid-day trading on Wednesday . The company traded as high as $8.30 and last traded at $8.25, 459,600 shares traded hands during trading. A decline of 62% from the average session volume of 1,203,550 shares. The stock had previously closed at $7.14.
A number of research analysts have issued reports on the stock. ValuEngine lowered shares of Bio-Path from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research upgraded shares of Bio-Path from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price target (down previously from $28.00) on shares of Bio-Path in a research note on Monday.
The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.85 and a current ratio of 13.85. The firm has a market cap of $23.79 million, a price-to-earnings ratio of -0.57 and a beta of 3.05. The stock’s 50 day simple moving average is $10.17 and its 200-day simple moving average is $11.98.
Bio-Path Company Profile (NASDAQ:BPTH)
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More: What causes a recession?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.